查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1195582

高級藥物輸送系統 (ADDS) 市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Advanced Drug Delivery Systems Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

高級藥物輸送系統 (ADDS) 市場預計在預測期內 (2022-2027) 的複合年增長率為 5.3%。

COVID-19 大流行對市場增長率產生了積極影響。 幾項研究強調了 ADDS 如何幫助為現有療法開發改進的遞送系統（劑型）。 例如，2020 年 6 月，瑞典查爾姆斯理工大學、哥德堡大學和阿斯利康啟動了一項新的關鍵研究，研究針對 COVID-19 的鼻腔噴霧 mRNA 疫苗，結合了許多有前途的概念。 該團隊研究了含有免疫增強劑和靶蛋白的仿生納米粒子，以探索鼻腔免疫的設計原理。 Chalmers Innovation Office、Chalmers Advanced Health Engineering Area、瑞典戰略研究基金會和瑞典研究委員會為這項工作做出了貢獻。

此外，2020 年 4 月，Bioavanta-Bosti 利用其 Novochizol 殼聚醣多醣納米技術，開發了一種適用於治療 COVID-19 患者的局部和緩釋肺內給藥製劑的 API。或開發了一個 48 小時的製造工藝來封裝生物製劑。 2020 年，Bioavanta-Bosti 還將與藥物開發人員和臨床研究人員合作，製造改變用途的藥物或新型分子或生物製劑，以治療肺部嚴重的 COVID-19 感染。我報告說我正在尋求合作關係。 ADDS 支持搜索新知識以識別未來目標分佈的未探索領域，並在製藥行業和學術機構中迅速傳播。 因此，COVID-19 對市場增長產生了重大影響。

此外，推動該市場增長的因素包括新藥和生物製劑的開發、對人類生物學和疾病的了解不斷加深，以及研發成本不斷增加。

生物學相關工作的多項進展正在創造獨特的機會，以更好地了解人類疾病的分子後果，並根據這些因素開發新藥和生物製品。. 最近發現的先進藥物遞送系統包括脂質、蛋白質和聚合物技術，可以提供良好的體內脂質分佈，防止藥物被外部環境降解，降低藥物清除率。 先進的藥物和生物製劑以較低的劑量更有效。 因此，它們必須得到先進的藥物輸送系統的支持才能發揮最大功效。

除了藥物和生物製劑，藥物洗脫植入物還有可能實現不間斷治療和減少藥物劑量（從而降低給藥頻率）。 先進的緩釋系統有助於治療腸道感染等疾病。 隨著自動注射器的發展趨勢以及生物製劑/生物仿製藥和自動注射器管道的迅速擴張，它們最近已成為一類重要的醫療器械。 許多公司都專注於推出有助於市場增長的新產品。 例如，2020 年 12 月，Agile Therapeutics, Inc. 在美國將 Twirla（左炔諾孕酮和乙炔雌二醇）透皮系統商業化，這是一種新的非常規、非侵入性避孕貼劑。 此外，2022 年 2 月，NewGen Medical Devices, Inc. 向台灣醫療分銷商信亞生物科技發出了 Insjet 無針注射器的採購訂單。 這是一項多年期銷售和分銷協議的一部分，前兩年至少需要 100,000 加元，其餘三年的未來承諾將按順序確認。 此類合同也有助於市場的增長。

同樣，duocap（膠囊中膠囊）、電膠囊、發光給藥監測技術（LDMT）等為配製難溶性化合物和監測藥物釋放動力學提供了新方法。靶向口服給藥的示例系統。 正在開發先進的藥物遞送系統以解決溶解度問題並使藥物更具親脂性。 這使得它很容易穿過體內的脂質屏障，最終防止光降解和pH變化等外部問題影響藥物，進而在所需位置輸送所需濃度，從而達到最大的治療效果。 . 因此，這些新興市場的發展有望對市場增長產生積極影響。

但是，先進給藥產品的產品召回以及使用納米藥物給藥的挑戰可能會阻礙市場增長。

先進藥物輸送系統的市場趨勢

按類型分，口服給藥系統細分市場在預測期內將保持高速增長

口服給藥是醫生和患者最常用和首選的給藥途徑。 對這種給藥途徑的大部分需求是由於攝入的便利性和廣泛的治療適應症的可用性，從而導致潛在的毒性和副作用較低。

隨著新藥開發、專利申請和營銷的成本和復雜性的增加，製藥公司同時認識到控製藥物遞送的治療益處，並對開發和改進口服釋放藥物遞送系統表現出極大的興趣。我正在發送。 在過去十年中，口服釋放給藥系統因其靈活性、降低給藥頻率和提高患者依從性而受到廣泛關注。 上述因素，加上口服控釋給藥系統的合理成本，導致了這種給藥途徑的流行。

在中樞神經系統、心血管、代謝和呼吸系統疾病等關鍵治療領域的市場擴張和新推出的控釋製劑的推動下，先進口服給藥系統的開發正在加速這是因為 例如，2020 年，Progenity 公佈了其口服給藥系統（DDS）DDS Capsules 的性能，該系統採用專有的自主立體定向技術，旨在定位胃腸道的迴腸/迴盲部區域。報告了良好的初步臨床前數據 該技術基於解剖學，旨在承受生理條件的變化，例如 pH 值、運動性和細菌。 此類產品的推出將為該行業在不久的將來提供增長機會。

口服薄膜藥物等先進的藥物輸送系統因其高臨床療效和抗病功效而受到越來越多的需求。 例如，2021年6月，Silpa Medicare Co., Ltd.推出商品名為“Morcil”的兒科撲熱息痛口服薄膜製劑。 Silpa在完全滿足生物等效性要求後，獲得了Morcil口服薄膜製劑的批准。 我們的撲熱息痛口服薄膜配方受專利保護，是世界上同類產品中的首創。

因此，由於上述因素，預計口服給藥領域在預測期內將會增長。

北美主導市場，預計在預測期內將繼續保持同樣的趨勢

北美目前主導著全球先進藥物輸送系統市場。 這是由於越來越多地採用改進的藥物輸送解決方案以及醫療保健中先進治療方法的跟進。 美國是該地區最大的市場。 對藥物自我管理的日益偏好、可注射藥物輸送系統的創新不斷增加、新醫療技術的廣泛採用以及慢性病的高患病率是美國先進藥物輸送系統市場的主要驅動力。它是

心髒病是導致該國人民、社區、醫療保健提供者和系統負擔的主要原因。 在美國，大約一半的成年人患有某種形式的心血管疾病。 據美國癌症協會預測，2022 年美國將診斷出近 200 萬新癌症病例，約 60.9 萬人將死於癌症。 如此高的疾病負擔創造了對先進藥物輸送系統的有效治療需求，並促進了市場的增長。

此外，市場參與者、非營利組織和政府機構的聯合舉措也在推動該地區的市場增長。 例如，2022 年 3 月，TFF Pharmaceuticals 將成為美國陸軍醫學研究與發展司令部和美國陸軍傳染病研究部的一部分，後者是美國陸軍針對生物武器進行防禦性研究的首要機構和設施 (USAMRIID) 以及日內瓦基金會，一個促進美國軍方創新醫學研究的非營利組織。 根據協議條款，TFF Pharmaceuticals 和 USAMRIID 將開發使用 TFF 的薄膜冷凍技術配製的干粉重組水泡性口炎病毒嚴重急性呼吸系統綜合症冠狀病毒 2 型糖蛋白（TFFD-RVSV-SARS2。-GP）將評估疫苗的免疫反應。 預計此類聯合舉措將推動市場增長。

因此，由於上述因素，預計北美地區在預測期內將出現增長。

先進藥物輸送系統市場的競爭對手分析

先進給藥系統市場的競爭很低。 藥物輸送系統的持續技術進步可能會在未來幾年引入新的進入者。 該市場的主要參與者包括波士頓科學公司、百特國際、Becton Dickinson & Company、Kindeva Drug Delivery L.P.

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 新藥和生物製品的開發
    • 在理解人類生物學和疾病方面取得的進展
    • 研發費用增加
  • 市場製約因素
    • 召回先進的給藥產品
    • 使用納米藥物輸送藥物的挑戰
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按類型
    • 口服給藥系統
    • 注射給藥系統
    • 用於吸入/呼吸系統的給藥系統
    • 透皮給藥系統
    • 跨粘膜給藥系統
    • 基於載體的給藥系統
    • 其他類型
  • 通過申請
    • 心血管疾病
    • 腫瘤學
    • 泌尿科
    • 糖尿病
    • 中樞神經系統
    • 眼科
    • 感染
    • 其他應用
  • 按技術
    • 前藥
    • 植入物和宮內節育器
    • 靶向給藥
    • 聚合物藥物輸送
    • 其他技術
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Baxter
    • Bayer AG
    • Boston Scientific Corporation
    • Kindeva Drug Delivery L.P.
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Medtronic
    • Ypsomed
    • Abbvie, Inc.
    • Astrazeneca

第7章 市場機會與今後動向

簡介目錄
Product Code: 53008

The advanced drug delivery systems (ADDS) market is expected to register a CAGR of 5.3% during the forecast period (2022-2027).

The COVID-19 pandemic had positively impacted the market's growth rate. Several studies emphasize how ADDS will help develop improved delivery systems (dosage forms) of existing therapeutic agents. For instance, in June 2020, the Chalmers University of Technology in Sweden, the University of Gothenburg, and AstraZeneca started new pivotal research combining many promising concepts to investigate a nasal spray mRNA vaccine against COVID-19. The team was working on a biomimetic nanoparticle that contains both immune enhancers and a targeting protein to investigate design principles for nasal immunization. The Chalmers Innovation Office, the Chalmers Area of Advance Health Engineering, the Swedish Foundation for Strategic Research, and the Swedish Research Council contributed to the initiative.

Additionally, in April 2020, Bioavanta-Bosti developed a 48-hour manufacturing process using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs or biologics for localized delivery and sustained release intra-pulmonary drug delivery formulations, which are suitable for treating COVID-19 patients. Bioavanta-Bosti also reported in 2020 that it is looking for collaborations with drug developers and clinical researchers to produce a repurposed medicine or new molecular or biological entity formulations to treat severe COVID-19 infection in the lungs. ADDS has aided in exploring new insights to identify untapped areas for future targeted distribution, and it is quickly gaining traction in the pharmaceutical sector and academic institutions. Thus, COVID-19 has had a significant impact on the growth of the market.

Furthermore, the factors driving this market's growth include the development of new drugs and biologics; advancements in understanding human biology and diseases; and increased R&D spending.

Advancements in several biology-oriented initiatives have created a unique opportunity to better understand the molecular effects of human diseases and develop novel drugs and biologics based on these factors. The recently discovered advanced drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced drug delivery systems to gain maximum efficacy.

In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and a reduction in drug dosage (hence a less frequent need for dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in December 2020, Agile Therapeutics, Inc., commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch in the United States. Additionally, in February 2022, Nu Gen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co., Ltd., for its InsuJet needleless injection system. This is part of a multi-year sales and distribution agreement with a minimum commitment of CDN 100,000 over the first two years, with future commitments for the remaining three years of the agreement to be finalized in due course. Such agreements are also contributing to the growth of the market.

Likewise, Duocap (capsule-in-a-capsule), electrocapsule, and light-up delivery monitoring technology (LDMT) are some of the controlled and targeted oral drug delivery systems that provide a new way of formulating poorly soluble compounds and monitoring the release rate of drugs. Advanced drug delivery systems are being developed to resolve solubility problems and make the drugs more lipid-soluble. Thus, this enables them to easily cross lipid barriers in the body, eventually preventing external issues, such as photodegradation and pH changes, from affecting the drug and further achieving the desired concentration at the desired location to provide the maximum therapeutic effect. Thus, these developments are expected to positively impact the market's growth.

However, product recalls of advanced drug delivery products and challenges in nanomedicine-based drug delivery may hinder the growth of the market.

Advanced Drug Delivery Systems Market Trends

The Oral Drug Delivery System Segment by Type to Hold the High Growth Over the Forecast Period

The oral drug delivery method is the most common and preferred drug administration route by the physician and the patient. The demand for this route of administration mostly lies in the convenience of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the possibility of toxicity and side effects.

With increasing costs and complications in developing, patenting, and marketing new drug entities, pharmaceutical companies, with simultaneous recognition of the therapeutic advantages of controlled drug delivery, are paying greater attention to developing and modifying oral-release drug delivery systems. Over the last decade, oral release drug delivery systems have received extensive attention owing to their flexibility, reduced dosing frequency, and better patient compliance. The aforesaid factors, in combination with the reasonable cost of oral controlled release drug delivery systems, led to greater adoption of this route of administration.

The accelerated pace of advanced oral drug delivery system development is fostered by a growing market of controlled release formulations and new launches in key therapeutic areas such as the central nervous system and cardiovascular, metabolic, and respiratory diseases. For instance, in 2020, Progenity Inc. reported positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule, which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract. This technology is based on anatomy and is designed to resist variability in physiological conditions like pH, motility, and bacteria. The launch of such products will provide growth opportunities for the segment in the near future.

The demand for advanced drug delivery systems such as oral thin-film drugs is rising due to their high clinical efficacy and effectiveness against diseases. For instance, in June 2021, Shilpa Medicare Ltd. launched an oral thin film formulation, a pediatric dose of paracetamol oral thin film, under the brand name Molshil. Shilpa received approval for Molshil oral thin films after sufficiently complying with bioequivalence requirements. Shilpa's Paracetamol oral thin films are patent protected and are the first of their kind in the world.

Thus, owing to the abovementioned factors, the oral drug delivery segment is expected to grow during the forecast period.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the global advanced drug delivery systems market owing to the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. The United States is the largest market in the region. The growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are the primary drivers for the United States advanced drug delivery systems market.

Heart disease is a leading cause of death that burdens people, communities, healthcare providers, and systems in the country. Nearly half of all adults in the United States have some form of cardiovascular disease. According to the American Cancer Society, nearly 2 million new cancer cases are expected to be diagnosed, and around 609,000 people will die from cancer in the United States in 2022. Such a high burden of diseases creates demand for advanced drug delivery systems for effective treatment and thus drives the growth of the market.

Additionally, the joint initiatives taken by the market players, non-profit organizations, and government agencies are also propelling the growth of the market in the region. For instance, in March 2022, TFF Pharmaceuticals, Inc. entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), part of the United States Army Medical Research and Development Command and the United States Army's premier institution and facility for defensive research into countermeasures against biological warfare, and the Geneva Foundation, a non-profit that advances innovative medical research within the United States military. As per the agreement, TFF Pharmaceuticals and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF's Thin Film Freezing technology. Such joint initiatives are also expected to propel the growth of the market.

Thus, owing to the abovementioned factors, the North American region is expected to show growth over the forecast period.

Advanced Drug Delivery Systems Market Competitor Analysis

The advanced drug delivery systems market is moderately competitive. Owing to the continuous technological advancements in the drug delivery system, there are possibilities for newer players to enter the market over the coming years. Some major players in this market are Boston Scientific Corporation, Baxter International, Becton, Dickinson and Company, Kindeva Drug Delivery L.P., and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Development of New Drugs and Biologics
    • 4.2.2 Advancements in Understanding Human Biology and Diseases
    • 4.2.3 Increased R&D Spending
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls of Advanced Drug Delivery Products
    • 4.3.2 Challenges in Nanomedicine-based Drug Delivery
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Oral Drug Delivery System
    • 5.1.2 Injection-based Drug Delivery System
    • 5.1.3 Inhalation/Pulmonary Drug Delivery System
    • 5.1.4 Transdermal Drug Delivery System
    • 5.1.5 Trans mucosal Drug Delivery System
    • 5.1.6 Carrier-based Drug Delivery System
    • 5.1.7 Other Types
  • 5.2 By Application
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncology
    • 5.2.3 Urology
    • 5.2.4 Diabetes
    • 5.2.5 Central Nervous System
    • 5.2.6 Ophthalmology
    • 5.2.7 Infections
    • 5.2.8 Other Applications
  • 5.3 By Technology
    • 5.3.1 Prodrug
    • 5.3.2 Implants and Intrauterine Devices
    • 5.3.3 Targeted Drug Delivery
    • 5.3.4 Polymeric Drug Delivery
    • 5.3.5 Other Technologies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Baxter
    • 6.1.4 Bayer AG
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Kindeva Drug Delivery L.P.
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Medtronic
    • 6.1.11 Ypsomed
    • 6.1.12 Abbvie, Inc.
    • 6.1.13 Astrazeneca

7 MARKET OPPORTUNITIES AND FUTURE TRENDS